Roche Acquires PathAI for $750 Million to Advance AI in Pathology
Roche has reached an agreement to purchase PathAI for $750 million, aiming to enhance the application of artificial intelligence in disease diagnosis by pathologists.
Editorial Staff
1 min read
Updated about 20 hours ago
In a significant move to bolster its capabilities in diagnostic technology, Roche has announced its acquisition of PathAI for $750 million.
This deal is intended to accelerate the integration of artificial intelligence into pathology, potentially improving the accuracy and efficiency of disease diagnoses.
As the healthcare sector increasingly embraces AI, Roche's investment reflects its commitment to advancing innovative solutions in medical diagnostics.